73 results
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
23 May 24
Other Events
5:41pm
, and Scientific Investigator, Northwell Health. Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
15 May 24
Results of Operations and Financial Condition
4:34pm
of Research and Development, and Chief Medical Officer, added, “We have continued to analyze and publish data from our first-in-human study characterizing
8-K
EX-99.1
ysnjo1 48lptzo
5 Apr 24
Other Events
4:33pm
8-K
EX-99.1
hvdbot 6r3
29 Mar 24
Results of Operations and Financial Condition
8:35am
8-K
EX-99.1
3owhr4g
17 Jan 24
Other Events
8:35am
8-K
EX-99.1
kfrlgtwnplcex
9 Jan 24
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
8:11am
8-K
EX-99.1
b8zy1z25nv
9 Nov 23
Results of Operations and Financial Condition
4:41pm
8-K
EX-99.1
6jgjmj
3 Nov 23
Other Events
5:10pm
8-K
EX-99.1
pui k66js4y5n2d5aaba
27 Sep 23
Other Events
5:41pm
8-K
EX-99.1
k5mwex 40931j
7 Sep 23
Other Events
8:00am
8-K/A
EX-99.2
3tzdorcmqi0zc1p wh4v
11 Aug 23
Elicio Therapeutics, Inc. Financial Statements
9:13pm
8-K/A
EX-99.1
juzp b7cek
11 Aug 23
Elicio Therapeutics, Inc. Financial Statements
9:13pm
8-K/A
EX-99.3
ejyodpj0qq97je248cwk
11 Aug 23
Elicio Therapeutics, Inc. Financial Statements
9:13pm